- Home
- LSH vs ANTX Comparison
LSH vs ANTX Comparison
Compare LSH & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSH
- ANTX
- Stock Information
- Founded
- LSH 2018
- ANTX 2017
- Country
- LSH United States
- ANTX United States
- Employees
- LSH N/A
- ANTX N/A
- Industry
- LSH
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- LSH
- ANTX Health Care
- Exchange
- LSH NYSE
- ANTX Nasdaq
- Market Cap
- LSH 28.6M
- ANTX 31.9M
- IPO Year
- LSH 2024
- ANTX 2022
- Fundamental
- Price
- LSH $2.54
- ANTX $1.23
- Analyst Decision
- LSH
- ANTX Hold
- Analyst Count
- LSH 0
- ANTX 5
- Target Price
- LSH N/A
- ANTX $3.50
- AVG Volume (30 Days)
- LSH 32.4K
- ANTX 918.3K
- Earning Date
- LSH 11-15-2024
- ANTX 11-13-2024
- Dividend Yield
- LSH N/A
- ANTX N/A
- EPS Growth
- LSH N/A
- ANTX N/A
- EPS
- LSH N/A
- ANTX N/A
- Revenue
- LSH $18,248,233.00
- ANTX N/A
- Revenue This Year
- LSH N/A
- ANTX N/A
- Revenue Next Year
- LSH N/A
- ANTX N/A
- P/E Ratio
- LSH N/A
- ANTX N/A
- Revenue Growth
- LSH 28.38
- ANTX N/A
- 52 Week Low
- LSH $2.10
- ANTX $0.87
- 52 Week High
- LSH $5.37
- ANTX $22.22
- Technical
- Relative Strength Index (RSI)
- LSH N/A
- ANTX 65.23
- Support Level
- LSH N/A
- ANTX $0.98
- Resistance Level
- LSH N/A
- ANTX $1.04
- Average True Range (ATR)
- LSH 0.00
- ANTX 0.07
- MACD
- LSH 0.00
- ANTX 0.02
- Stochastic Oscillator
- LSH 0.00
- ANTX 52.58
About LSH LAKESIDE HOLDING LTD
Lakeside Holding Ltd i a U.S.-based integrated cross-border supply chain solution provider with a strategic focus on the Asian market including China and South Korea. It provides customized cross-border ocean freight solutions and airfreight solutions in the U.S, including (i) cross-border freight consolidation and forwarding services, (ii) customs clearance services, (iii) warehousing and distribution services and (iv) U.S. domestic ground transportation services.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.